Keros Therapeutics, Inc. (KROS) is gearing up to report long-term results from its phase 2 study using KER-050 [elritercept] for the treatment of patients with myelodysplastic syndrome [MDS]. Matter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results